<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39364130</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2186-6953</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>4</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Bioscience of microbiota, food and health</Title><ISOAbbreviation>Biosci Microbiota Food Health</ISOAbbreviation></Journal><ArticleTitle>Effect of multi-strain bifidobacteria supplementation on intestinal microbiota development in low birth weight neonates: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>352</StartPage><EndPage>358</EndPage><MedlinePgn>352-358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12938/bmfh.2023-093</ELocationID><Abstract><AbstractText>Single-strain <i>Bifidobacterium</i> species are commonly used as probiotics with low birth weight neonates. However, the effectiveness and safety of multi-strain <i>Bifidobacterium</i> supplementation are not well known. Thirty-six neonates weighing less than 2,000 g (558-1,943 g) at birth and admitted to a neonatal intensive care unit were randomly assigned to receive a single strain or triple strains of <i>Bifidobacterium</i> with lactulose enterally for 4 weeks from birth. The relative abundances of <i>Staphylococcus</i> and <i>Bifidobacterium</i> in the fecal microbiota at weeks 1, 2, and 4 were investigated. Based on the study results, no significant difference was detected between the two groups in the abundance of <i>Staphylococcus</i>; however, the triple-strain group had significantly high abundances of <i>Bifidobacterium</i> at weeks 2 and 4. The fecal microbiota in the triple-strain group had significantly lower alpha diversity (<i>Bifidobacterium</i>-enriching) after week 4 and was different from that in the single-strain group, which showed a higher abundance of <i>Clostridium.</i> No severe adverse events occurred in either group during the study period. Although no significant difference was detected between single- and multi-strain bifidobacteria supplementation in the colonization of <i>Staphylococcus</i> in the fecal microbiota of the neonates, multi-strain bifidobacteria supplementation contributed toward early enrichment of the microbiota with bifidobacteria and suppression of other pathogenic bacteria, such as <i>Clostridium</i> spp.</AbstractText><CopyrightInformation>©2024 BMFH Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takeshita</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Chiba Rosai Hospital, 2-16 Tatsumidaihigashi, Ichihara-shi, Chiba 290-0003, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takei</LastName><ForeName>Haruka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Saori</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hishiki</LastName><ForeName>Haruka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iijima</LastName><ForeName>Yuta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perinatal Medical Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogata</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perinatal Medical Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujishiro</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perinatal Medical Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tominaga</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perinatal Medical Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konno</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perinatal Medical Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwase</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perinatal Medical Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Endo</LastName><ForeName>Mamiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perinatal Medical Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishiwada</LastName><ForeName>Naruhiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Medical Mycology Research Center, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8673, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osone</LastName><ForeName>Yoshiteru</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perinatal Medical Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takemura</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamada</LastName><ForeName>Hiromichi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimojo</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Preventive Medical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Biosci Microbiota Food Health</MedlineTA><NlmUniqueID>101578264</NlmUniqueID><ISSNLinking>2186-3342</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">low birth weight neonates</Keyword><Keyword MajorTopicYN="N">multi-strain bifidobacteria</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList><CoiStatement>Morinaga Milk Industry Co., Ltd. was not the sponsor of this study but did supply the probiotic products free of cost for the trial.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>11</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364130</ArticleId><ArticleId IdType="pmc">PMC11444860</ArticleId><ArticleId IdType="doi">10.12938/bmfh.2023-093</ArticleId><ArticleId IdType="pii">2023-093</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Henderickx JGE, Zwittink RD, van Lingen RA, Knol J, Belzer C. 2019. The preterm gut microbiota: an inconspicuous challenge in nutritional neonatal care. Front Cell Infect Microbiol 9: 85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454191</ArticleId><ArticleId IdType="pubmed">31001489</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamburini S, Shen N, Wu HC, Clemente JC. 2016. The microbiome in early life: implications for health outcomes. Nat Med 22: 713–722.</Citation><ArticleIdList><ArticleId IdType="pubmed">27387886</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuels N, van de Graaf RA, de Jonge RCJ, Reiss IKM, Vermeulen MJ. 2017. Risk factors for necrotizing enterocolitis in neonates: a systematic review of prognostic studies. BMC Pediatr 17: 105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391569</ArticleId><ArticleId IdType="pubmed">28410573</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart CJ, Marrs ECL, Magorrian S, Nelson A, Lanyon C, Perry JD, Embleton ND, Cummings SP, Berrington JE. 2012. The preterm gut microbiota: changes associated with necrotizing enterocolitis and infection. Acta Paediatr 101: 1121–1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">22845166</ArticleId></ArticleIdList></Reference><Reference><Citation>Murgas Torrazza R, Neu J. 2011. The developing intestinal microbiome and its relationship to health and disease in the neonate. J Perinatol 31Suppl 1: S29–S34.</Citation><ArticleIdList><ArticleId IdType="pubmed">21448201</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozé JC, Ancel PY, Lepage P, Martin-Marchand L, Al Nabhani Z, Delannoy J, Picaud JC, Lapillonne A, Aires J, Durox M, et al. Nutrition EPIPAGE 2 study group EPIFLORE Study Group. 2017. Nutritional strategies and gut microbiota composition as risk factors for necrotizing enterocolitis in very-preterm infants. Am J Clin Nutr 106: 821–830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573022</ArticleId><ArticleId IdType="pubmed">28659297</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehin C, Dubois D, Dicky O, Breinig S, Oswald E, Serino M. 2020. Evolution of gut microbiome and metabolome in suspected necrotizing enterocolitis: a case-control study. J Clin Med 9: 1–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7408695</ArticleId><ArticleId IdType="pubmed">32709038</ArticleId></ArticleIdList></Reference><Reference><Citation>Martí M, Spreckels JE, Ranasinghe PD, Wejryd E, Marchini G, Sverremark-Ekström E, Jenmalm MC, Abrahamsson T. 2021. Effects of Lactobacillus reuteri supplementation on the gut microbiota in extremely preterm infants in a randomized placebo-controlled trial. Cell Rep Med 2: 100206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7974321</ArticleId><ArticleId IdType="pubmed">33763652</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan RL, Preidis GA, Kashyap PC, Weizman AV, Sadeghirad B, Chang Y, Florez ID, Foroutan F, Shahid S, Zeraatkar D, McMaster Probiotic, Prebiotic, and Synbiotic Work Group. 2020. Probiotics reduce mortality and morbidity in preterm, low-birth-weight infants: a systematic review and network meta-analysis of randomized trials. Gastroenterology 159: 467–480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014956</ArticleId><ArticleId IdType="pubmed">32592699</ArticleId></ArticleIdList></Reference><Reference><Citation>Horigome A, Hisata K, Odamaki T, Iwabuchi N, Xiao JZ, Shimizu T. 2021. Colonization of supplemented Bifidobacterium breve M-16V in low birth weight infants and its effects on their gut microbiota weeks post-administration. Front Microbiol 12: 610080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058467</ArticleId><ArticleId IdType="pubmed">33897631</ArticleId></ArticleIdList></Reference><Reference><Citation>Patole S, Keil AD, Chang A, Nathan E, Doherty D, Simmer K, Esvaran M, Conway P. 2014. Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates—a randomised double blind placebo controlled trial. PLoS One 9: e89511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3940439</ArticleId><ArticleId IdType="pubmed">24594833</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga TD, da Silva GAP, de Lira PIC, de Carvalho Lima M. 2011. Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial. Am J Clin Nutr 93: 81–86.</Citation><ArticleIdList><ArticleId IdType="pubmed">20980486</ArticleId></ArticleIdList></Reference><Reference><Citation>Costeloe K, Hardy P, Juszczak E, Wilks M, Millar MR, Probiotics in Preterm Infants Study Collaborative Group 2016. Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial. Lancet 387: 649–660.</Citation><ArticleIdList><ArticleId IdType="pubmed">26628328</ArticleId></ArticleIdList></Reference><Reference><Citation>Rougé C, Piloquet H, Butel MJ, Berger B, Rochat F, Ferraris L, Des Robert C, Legrand A, de la Cochetière MF, N’Guyen JM, et al. 2009. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 89: 1828–1835.</Citation><ArticleIdList><ArticleId IdType="pubmed">19369375</ArticleId></ArticleIdList></Reference><Reference><Citation>Härtel C, Pagel J, Spiegler J, Buma J, Henneke P, Zemlin M, Viemann D, Gille C, Gehring S, Frommhold D, et al. 2017. Lactobacillus acidophilus/Bifidobacterium infantis probiotics are associated with increased growth of VLBWI among those exposed to antibiotics. Sci Rep 7: 5633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5514087</ArticleId><ArticleId IdType="pubmed">28717131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosomi K, Ohno H, Murakami H, Natsume-Kitatani Y, Tanisawa K, Hirata S, Suzuki H, Nagatake T, Nishino T, Mizuguchi K, et al. 2017. Method for preparing DNA from feces in guanidine thiocyanate solution affects 16S rRNA-based profiling of human microbiota diversity. Sci Rep 7: 4339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5489508</ArticleId><ArticleId IdType="pubmed">28659635</ArticleId></ArticleIdList></Reference><Reference><Citation>Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao JZ, Abe F, Osawa R. 2016. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. BMC Microbiol 16: 90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879732</ArticleId><ArticleId IdType="pubmed">27220822</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. 2016. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 13: 581–583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4927377</ArticleId><ArticleId IdType="pubmed">27214047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikorska H, Smoragiewicz W. 2013. Role of probiotics in the prevention and treatment of meticillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents 42: 475–481.</Citation><ArticleIdList><ArticleId IdType="pubmed">24071026</ArticleId></ArticleIdList></Reference><Reference><Citation>Piewngam P, Otto M. 2020. Probiotics to prevent Staphylococcus aureus disease? Gut Microbes 11: 94–101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6973312</ArticleId><ArticleId IdType="pubmed">30913972</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas JP, Raine T, Reddy S, Belteki G. 2017. Probiotics for the prevention of necrotising enterocolitis in very low-birth-weight infants: a meta-analysis and systematic review. Acta Paediatr 106: 1729–1741.</Citation><ArticleIdList><ArticleId IdType="pubmed">28471478</ArticleId></ArticleIdList></Reference><Reference><Citation>Aceti A, Maggio L, Beghetti I, Gori D, Barone G, Callegari ML, Fantini MP, Indrio F, Meneghin F, Morelli L, et al. Italian Society of Neonatology. 2017. Probiotics prevent late-onset sepsis in human milk-fed, very low birth weight preterm infants: systematic review and meta-analysis. Nutrients 9: 1–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5579697</ArticleId><ArticleId IdType="pubmed">28829405</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Marwah G, Westgarth M, Buys N, Ellwood D, Gray PH. 2017. Effects of probiotics on necrotizing enterocolitis, sepsis, intraventricular hemorrhage, mortality, length of hospital stay, and weight gain in very preterm infants: a meta-analysis. Adv Nutr 8: 749–763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5593111</ArticleId><ArticleId IdType="pubmed">28916575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizeki S, Sugita M, Takata M, Yaeshima T. 2013. Effect of administration of bifidobacteria on intestinal microbiota in low-birth-weight infants and transition of administered bifidobacteria: a comparison between one-species and three-species administration. Anaerobe 23: 38–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">23988359</ArticleId></ArticleIdList></Reference><Reference><Citation>Athalye-Jape G, Esvaran M, Patole S, Simmer K, Nathan E, Doherty D, Keil A, Rao S, Chen L, Chandrasekaran L, et al. 2022. Effect of single versus multistrain probiotic in extremely preterm infants: a randomised trial. BMJ Open Gastroenterol 9: 1–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8860036</ArticleId><ArticleId IdType="pubmed">35185013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojima MN, Jiang L, Arzamasov AA, Yoshida K, Odamaki T, Xiao J, Nakajima A, Kitaoka M, Hirose J, Urashima T, et al. 2022. Priority effects shape the structure of infant-type Bifidobacterium communities on human milk oligosaccharides. ISME J 16: 2265–2279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381805</ArticleId><ArticleId IdType="pubmed">35768643</ArticleId></ArticleIdList></Reference><Reference><Citation>Roswall J, Olsson LM, Kovatcheva-Datchary P, Nilsson S, Tremaroli V, Simon MC, Kiilerich P, Akrami R, Krämer M, Uhlén M, et al. 2021. Developmental trajectory of the healthy human gut microbiota during the first 5 years of life. Cell Host Microbe 29: 765–776.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">33794185</ArticleId></ArticleIdList></Reference><Reference><Citation>Derrien M, Alvarez AS, de Vos WM. 2019. The gut microbiota in the first decade of life. Trends Microbiol 27: 997–1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">31474424</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi C, Xue Y, Lv N, Hao Y, Liu R, Wang Y, Ding X, Zeng H, Li G, Shen Q, et al. 2019. Longitudinal gut bacterial colonization and its influencing factors of low birth weight infants during the first 3 months of life. Front Microbiol 10: 1105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6529567</ArticleId><ArticleId IdType="pubmed">31156608</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuki T, Yahagi K, Mori H, Matsumoto H, Hara T, Tajima S, Ogawa E, Kodama H, Yamamoto K, Yamada T, et al. 2016. A key genetic factor for fucosyllactose utilization affects infant gut microbiota development. Nat Commun 7: 11939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931012</ArticleId><ArticleId IdType="pubmed">27340092</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassir N, Benamar S, Khalil JB, Croce O, Saint-Faust M, Jacquot A, Million M, Azza S, Armstrong N, Henry M, et al. 2015. Clostridium butyricum strains and dysbiosis linked to necrotizing enterocolitis in preterm neonates. Clin Infect Dis 61: 1107–1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">26084844</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Wang B, Lu T, Pei Y. 2022. Safety and efficacy of probiotics in the prevention of necrotizing enterocolitis in premature and/or low-birthweight infants: a systematic review and meta-analysis. Transl Pediatr 11: 249–259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905096</ArticleId><ArticleId IdType="pubmed">35282017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zbinden A, Zbinden R, Berger C, Arlettaz R. 2015. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 107: 56–59.</Citation><ArticleIdList><ArticleId IdType="pubmed">25402825</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, Uchida T, Kuwana S, Sasaki K, Watanabe T, Saito J, Kawaji T. 2016. Bacteremia induced by Bifidobacterium breve in a newborn with cloacal exstrophy. Pediatr Int 58: 1226–1228.</Citation><ArticleIdList><ArticleId IdType="pubmed">27882741</ArticleId></ArticleIdList></Reference><Reference><Citation>AlFaleh K, Anabrees J. 2014. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev CD005496.</Citation><ArticleIdList><ArticleId IdType="pubmed">24723255</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>